Investigating BGB-26808 alone or with Tislelizumab for advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This open-label, multicenter, nonrandomized study evaluates the safety and efficacy of BGB-26808, both as a standalone treatment and in combination with Tislelizumab, in patients with advanced solid tumors. The study aims to determine the recommended dosing for BGB-26808 through a dose escalation and expansion approach. Participants will be monitored for their response to the treatment and any associated side effects.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Able to provide a signed and dated written informed consent prior to any study-specific procedures, sampling, or data collection.
2. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1.
3. Phase 1a: Participants with histologically or cytologically confirmed advanced, metastatic, and unresectable solid tumors that are immune-sensitive who have previously received standard systemic therapy, or for whom treatment is not available or not tolerated, or for whom treatment is determined not appropriate based on investigator's judgment and who have not received prior therapy targeting hematopoietic progenitor kinase 1 (HPK1).
4. Phase 1b: Participants with histologically confirmed locally advanced unresectable or metastatic tumor types and who have not had prior systemic treatment. Participants who received prior systemic therapy in a neo-adjuvant or adjuvant setting with curative intent for nonmetastatic disease must have experienced a disease-free interval of ≥ 6 months from the last dose of systemic therapy prior to the first dose of study treatments.
5. ≥ 1 measurable lesion per RECIST v1.1.
6. Able to provide an archived tumor tissue sample.
7. Adequate organ function.
8. Females of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study, and for ≥ 90 days after the last dose of BGB-26808, or for ≥ 120 days after the last dose of tislelizumab, or for up to ≥ 270 days after the last dose of chemotherapy.
9. Nonsterile males must be willing to use a highly effective method of birth control for the duration of the study treatment period and for ≥ 90 days after the last dose of BGB-26808, or for ≥ 120 days after the last dose of tislelizumab, or for ≥ 180 days after the last dose of chemotherapy.

Exclusion Criteria:

1. Prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-TIGIT, anti-CTLA4, or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways.
2. Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage or medical intervention.
3. Clinically significant bleeding from the gastrointestinal tract within 28 days before the first dose of study treatment(s).
4. Active leptomeningeal disease or uncontrolled, untreated brain metastasis.
5. Active autoimmune diseases or history of autoimmune diseases that may relapse
6. Any malignancy ≤ 3 years before the first dose of study treatment(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast).
7. Any condition that required systemic treatment with either corticosteroids (\> 10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤ 14 days before the first dose of study treatment(s).
8. History of interstitial lung disease, noninfectious pneumonitis, or uncontrolled lung diseases including pulmonary fibrosis, acute lung diseases.
9. Uncontrolled diabetes.
10. Infection (including tuberculosis infection) requiring systemic (oral or intravenous) antibacterial, antifungal, or antiviral therapy ≤ 14 days before the first dose of study treatment(s).

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Where it's running

• City of Hope National Medical Center
  Duarte, California, United States Recruiting
• University of Southern California Norris Comprehensive
  Los Angeles, California, United States Recruiting
• Yale University Yale Cancer Center
  New Haven, Connecticut, United States Recruiting
• Sylvester Cancer Center, University of Miami
  Miami, Florida, United States Recruiting
• University of Michigan Health System
  Ann Arbor, Michigan, United States Recruiting
• John Theurer Cancer Center Hackensack University Medical Center
  Hackensack, New Jersey, United States Recruiting

Study contacts

• Study coordinator: Study Director
• Email: clinicaltrials@beonemed.com
• Phone: 1.877.828.5568

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MSK-TCR5 in adults with advanced solid tumors that have KRAS/HRAS/NRAS G12D

  This study tests MSK-TCR5 to see if it is safe for adults with advanced solid tumors carrying a KRAS, HRAS, or NRAS G12D mutation.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07638371

• GTB-5550 treatment for people with advanced solid tumors.

  This Phase 1 trial tests GTB-5550, a B7-H3-targeting natural killer (NK) cell engager, in adults with advanced solid tumors who have exhausted or are ineligible for standard treatments.

  Recruiting Phase 1 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT07541573

• BSI-082 Alone or with Trastuzumab Deruxtecan in Advanced Solid Tumors

  This early-stage study tests BSI-082 by itself and then with Trastuzumab deruxtecan to see if higher doses are safe and tolerable in adults with advanced or metastatic solid tumors.

  Recruiting Phase 1 The University of Texas Health Science Center at San Antonio · San Antonio, Texas · NCT07086768

• Testing XB628 for advanced or metastatic solid tumors

  This study is testing a new treatment called XB628 to see if it can help people with advanced or metastatic solid tumors by finding the right dose that is safe and effective.

  Recruiting at 11 sites Phase 1 Exelixis · San Francisco, California and 10 other locations · NCT06952010

• Evaluating NKT3964 for Adults with Advanced Solid Tumors

  This study is testing a new drug called NKT3964 to see if it can safely help adults with advanced solid tumors, like ovarian or triple-negative breast cancer, after other treatments have failed.

  Recruiting at 17 sites Phase 1 NiKang Therapeutics, Inc. · Little Rock, Arkansas and 20 other locations · NCT06586957

• Evaluating a new treatment combining low dose radiotherapy and immunotherapy for bulky tumors

  This study is testing a new treatment that combines low dose radiation and an immunotherapy drug to see if it can help people with large tumors that haven't improved with standard treatments.

  Recruiting Phase 1 Sichuan University · Chengdu, Sichuan · NCT06349837

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.